The Expanding Role of Imaging in Theranostic Trials for Hematologic Malignancies
Theranostics is transforming the role of imaging in clinical trials, including those for hematologic malignancies, by aligning diagnosis and targeted treatment within the same framework. By combining molecular imaging with radioligand therapy, it not only helps identify eligible patients but also improves assessment of disease distribution and longitudinal monitoring of treatment response. As clinical trials grow more complex, consistent, high-quality imaging has become a critical foundation for successful trial execution and outcomes.
Hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, present unique challenges in clinical trials due to their biological heterogeneity, frequent bone marrow involvement, and diffuse patterns of disease. Traditional response assessments typically rely on a combination of imaging and critical clinical data. Recent advances in PET and SPECT imaging, combined with beta- and alpha-emitting radiopharmaceuticals, have expanded the role of imaging beyond detection to include patient stratification, dosimetry, and longitudinal response evaluation. Across the industry, there is growing emphasis on theranostic trial designs, imaging-based biomarkers, and standardized imaging endpoints to support regulatory submissions and enable more personalized treatment strategies.
Imaging Endpoints (IE) is at the forefront of this evolution, helping sponsors successfully integrate advanced imaging into theranostic and radioligand therapy trials. These studies require robust imaging endpoint strategies capable of quantifying whole-body tumor burden, bone marrow involvement, and minimal residual disease using PET and SPECT, while maintaining consistency across global multicenter trials. As the field advances toward alpha-emitter therapies and immunoPET-guided trial designs, IE continues to align imaging methodologies with evolving regulatory expectations. Through strategic centralized image review, harmonized protocols, and deep hematology expertise, IE optimizes the opportunity to demonstrate efficacy.
Imaging Endpoints continues to set the standard for imaging excellence in hematologic oncology by combining scientific rigor with operational precision. For more information,
